Plant Name: Linum usitatissimum
Taxonomic Information:
Plant ID: NPO25114
Plant Latin Name: Linum usitatissimum
Taxonomy Genus: Linum
Taxonomy Family: Linaceae
Plant External Links:
NCBI TaxonomyDB:
4006
Plant-of-the-World-Online:
n.a.
Used in Medicines:
Country/Region:
Turkey; Canada; Italy; India; Finland; Lebanon; Jordan; Chile; China; Argentina; Iraq; Spain; BulgariaTraditional Medicine System:
Sowa-Rigpa; Indian Folk; Unani; Siddha; Ayurveda; TCM; HomeopathyMedicinal Functions:
Analgesic; Cancer; Cardiotonic; Demulcent; Emollient; Expectorant; Laxative; Nervine; Pectoral; Resolvent; VD
Geographical Distribution:
Canada; Turkey; Italy; Lebanon; Finland; India; China; Chile; Jordan; Argentina; Iraq; Spain; Bulgaria
Example Image
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; NPSR1; | |
| FFAR1; FFAR4; CHRM1; CHRM2; CHRM3; CHRM5; | |
| CACNA1C; | |
| CA2; | |
| AR; NR3C2; PGR; NR3C1; | |
| PPARA; | |
| HSD17B10; ALOX15; HSD17B3; ALDH1A1; | |
| MMP9; MMP1; MMP2; | |
| HIF1A; NFKB1; | |
| PAX8; LMNA; RAB9A; NPC1; FABP3; FABP5; SHBG; SERPINA6; FABP4; MAPT; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | HSD17B3 | Estradiol 17-beta-dehydrogenase 3 | P37058 | CHEMBL4234 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
| Nuclear hormone receptor subfamily 3 group C | NR3C2 | Mineralocorticoid receptor | P08235 | CHEMBL1994 |
| Nuclear hormone receptor subfamily 3 group C | PGR | Progesterone receptor | P06401 | CHEMBL208 |
| Nuclear hormone receptor subfamily 3 group C | NR3C1 | Glucocorticoid receptor | P04150 | CHEMBL2034 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Small molecule receptor (family A GPCR) | CHRM1 | Muscarinic acetylcholine receptor M1 | P11229 | CHEMBL216 |
| Small molecule receptor (family A GPCR) | CHRM2 | Muscarinic acetylcholine receptor M2 | P08172 | CHEMBL211 |
| Small molecule receptor (family A GPCR) | CHRM3 | Muscarinic acetylcholine receptor M3 | P20309 | CHEMBL245 |
| Small molecule receptor (family A GPCR) | CHRM5 | Muscarinic acetylcholine receptor M5 | P08912 | CHEMBL2035 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Unclassified | PAX8 | Paired box protein Pax-8 | Q06710 | CHEMBL2362980 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | SHBG | Testis-specific androgen-binding protein | P04278 | CHEMBL3305 |
| Unclassified | SERPINA6 | Corticosteroid binding globulin | P08185 | CHEMBL2421 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Voltage-gated calcium channel | CACNA1C | Voltage-gated L-type calcium channel alpha-1C subunit | Q13936 | CHEMBL1940 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0005496; steroid binding | 4.853E-12 | 5.284E-08 | AR, CYP3A4, NPC1, NR3C1, NR3C2, PGR, SERPINA6, SHBG |
| BP | GO:0050896; response to stimulus | GO:0007197; adenylate cyclase-inhibiting G-protein coupled acetylcholine receptor signaling pathway | 6.356E-11 | 3.460E-07 | CHRM1, CHRM2, CHRM3, CHRM5 |
| MF | GO:0060089; molecular transducer activity | GO:0016907; G-protein coupled acetylcholine receptor activity | 6.356E-11 | 3.460E-07 | CHRM1, CHRM2, CHRM3, CHRM5 |
| BP | GO:0050896; response to stimulus | GO:0007207; phospholipase C-activating G-protein coupled acetylcholine receptor signaling pathway | 1.904E-10 | 8.292E-07 | CHRM1, CHRM2, CHRM3, CHRM5 |
| MF | GO:0005488; binding | GO:0005497; androgen binding | 2.806E-08 | 6.110E-05 | ALDH1A1, AR, SHBG |
| MF | Unclassified; | GO:0004872; receptor activity | 9.454E-08 | 1.494E-04 | AR, CHRM1, CHRM2, CHRM3, CHRM5, FFAR1, FFAR4, NPC1, NPSR1, NR3C1, NR3C2, PAX8, PGR, PPARA, TSHR |
| MF | GO:0060089; molecular transducer activity | GO:0003707; steroid hormone receptor activity | 1.039E-07 | 1.494E-04 | AR, NR3C1, NR3C2, PGR, PPARA |
| BP | GO:0023052; signaling | GO:0007271; synaptic transmission, cholinergic | 2.163E-07 | 2.479E-04 | CHRM1, CHRM2, CHRM3, CHRM5 |
| MF | GO:0005488; binding | GO:0005504; fatty acid binding | 2.163E-07 | 2.479E-04 | FABP3, FABP4, FABP5, FFAR4 |
| BP | GO:0009987; cellular process | GO:0038194; thyroid-stimulating hormone signaling pathway | 3.769E-06 | 2.345E-03 | PAX8, TSHR |
| MF | GO:0060089; molecular transducer activity | GO:0004996; thyroid-stimulating hormone receptor activity | 3.769E-06 | 2.345E-03 | PAX8, TSHR |
| BP | GO:0009987; cellular process | GO:0043401; steroid hormone mediated signaling pathway | 5.368E-06 | 2.922E-03 | AR, NR3C1, NR3C2, PGR, PPARA |
| BP | GO:0022414; reproductive process | GO:0060748; tertiary branching involved in mammary gland duct morphogenesis | 1.129E-05 | 5.588E-03 | AR, PGR |
| BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 1.474E-05 | 6.424E-03 | AR, NR3C1, NR3C2, PGR, PPARA |
| MF | GO:0140110; transcription regulator activity | GO:0001077; transcriptional activator activity, RNA polymerase II proximal promoter sequence-specific DNA binding | 1.424E-05 | 6.424E-03 | AR, HIF1A, NR3C1, PAX8, PGR, PPARA |
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 1.568E-05 | 6.566E-03 | FABP3, FABP4, FABP5 |
| BP | GO:0008152; metabolic process | GO:0032963; collagen metabolic process | 1.900E-05 | 7.662E-03 | HIF1A, MMP1, MMP2, MMP9 |
| MF | GO:0003824; catalytic activity | GO:0004435; phosphatidylinositol phospholipase C activity | 1.989E-05 | 7.873E-03 | CHRM1, CHRM3, CHRM5 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 2.151E-05 | 8.365E-03 | AR, CA2, MMP1, MMP2, MMP9, NR3C1, NR3C2, PGR, PPARA |
| BP | GO:0008152; metabolic process | GO:0008209; androgen metabolic process | 2.224E-05 | 8.497E-03 | CYP19A1, CYP3A4, HSD17B3 |
| BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 2.408E-05 | 9.024E-03 | HIF1A, MMP1, MMP2, MMP9 |
| BP | GO:0051179; localization | GO:0046903; secretion | 2.445E-05 | 9.024E-03 | CA2, CHRM1, CHRM3, CHRM5, FABP5, FFAR1, FFAR4, HIF1A, MMP9, NFKB1 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09150 Organismal Systems | 09152 Endocrine system | hsa03320 | PPAR signaling pathway | 1.938E-07 | 2.287E-05 | FABP3, FABP4, FABP5, MMP1, PPARA |
| 09150 Organismal Systems | 09156 Nervous system | hsa04725 | Cholinergic synapse | 2.086E-06 | 8.205E-05 | CHRM2, CHRM3, CHRM1, CHRM5, CACNA1C |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 1.906E-06 | 8.205E-05 | CHRM2, CHRM1, CACNA1C, PPARA, NFKB1, TSHR |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 8.547E-06 | 2.521E-04 | AR, PAX8, MMP1, MMP2, HIF1A, MMP9, NFKB1 |
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 1.272E-05 | 3.002E-04 | CHRM2, CHRM3, CHRM1, CHRM5, NR3C1, TSHR |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04020 | Calcium signaling pathway | 2.204E-05 | 4.334E-04 | CHRM2, CHRM3, CHRM1, CHRM5, CACNA1C |
| 09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 6.417E-05 | 1.082E-03 | MMP1, MMP2, MMP9 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 1.817E-04 | 2.680E-03 | HSD17B3, CYP3A4, CYP19A1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04911 | Insulin secretion | 5.613E-04 | 7.359E-03 | CHRM3, FFAR1, CACNA1C |
| 09140 Cellular Processes | 09142 Cell motility | hsa04810 | Regulation of actin cytoskeleton | 7.074E-04 | 8.347E-03 | CHRM2, CHRM3, CHRM1, CHRM5 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR; |
| Z00-Z99: Factors influencing health status and contact with health services | Female contraception | Z30 | PGR; |
| N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR; |
| C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Xerophthalmia | E50.6-E50.7 | NR3C1; |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | RAB9A; |
| NA: NA | Functional bowel syndrome | NA | CHRM1; |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | NR3C1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR; NR3C1; |
| NA: NA | Dystonia | NA | CHRM1; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2; |
| NA: NA | Schizoaffective disorders | NA | CHRM1; |
| NA: NA | Corticosteroid-responsive inflammation | NA | NR3C1; |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR; PGR; |
| NA: NA | Obstructive airway diseases | NA | SERPINA6; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | MMP9; |
| I00-I99: Diseases of the circulatory system | Congestive heart failure | I50 | NR3C2; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | NR3C1; |
| C00-D49: Neoplasms | Uterine fibroids | D25 | PGR; |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9; |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | CHRM1; CHRM2; CHRM3; CHRM5; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | CHRM1; CHRM5; MAPT; |
| K00-K95: Diseases of the digestive system | Colitis | K50-K52 | CHRM5; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | CHRM1; |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | NR3C2; |
| H00-H59: Diseases of the eye and adnexa | Diabetic retinopathy | H36, E10.3, E11.3, E13.3 | SERPINA6; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | NR3C2; MMP1; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnosing bronchial hyperreactivity | W88 | CHRM3; |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; NR3C1; NR3C2; FFAR1; |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | NR3C1; CHRM1; CHRM3; CHRM5; |
| I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | CACNA1C; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | NR3C1; |
| C00-D49: Neoplasms | Prostate cancer | C61 | AR; |
| O00-O9A: Pregnancy, childbirth and the puerperium | Premature labour | O60.1, P07.3 | PGR; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Visceral spasms | R25.2 | CHRM1; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | CHRM1; CHRM2; |
| K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | CHRM1; CHRM2; |
| K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR; |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | CHRM3; |
| NA: NA | Addiction | NA | CHRM2; |
| C00-D49: Neoplasms | Uterine leiomyoma | D25 | PGR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR; |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT; |
| G00-G99: Diseases of the nervous system G00-G99 | Central and peripheral nervous diseases | G96.9 | CHRM5; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Amnesia | F04 | CHRM5; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | CHRM1; CHRM2; CHRM3; MAPT; |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | NR3C1; CHRM5; |
| NA: NA | Male hypogonadism | NA | AR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Sjogren's syndrome | M35.0 | CHRM3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Severe mood disorders | F30-F39 | NR3C1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Skin allergies | T78.4 | NR3C1; |
| C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR; |
| I00-I99: Diseases of the circulatory system | Cardiac failure | I50 | CACNA1C; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR; CHRM2; NR3C2; |
| C00-D49: Neoplasms | Advanced breast carcinoma | NA | PGR; |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Addison's disease | E27.1-E27.2 | NR3C2; |
| N00-N99: Diseases of the genitourinary system | Chronic kidney disease | N18 | NR3C2; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | NR3C1; CHRM2; SERPINA6; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | PGR; |
| NA: NA | Excessive sweating | NA | CHRM1; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; MMP9; MMP2; |
| NA: NA | Spasms | NA | CHRM3; |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR; |
| C00-D49: Neoplasms | Cancer | C00-C96 | AR; NFKB1; HIF1A; NR3C1; MMP9; NR3C2; PGR; MMP2; |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; PGR; |
| C00-D49: Neoplasms | Endometrial cancer | C54.1 | PGR; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Spinal cord injury | S14, S24, S34 | NR3C1; |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | CHRM5; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; NR3C1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | NR3C1; MMP1; |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | NR3C1; |
| G00-G99: Diseases of the nervous system G00-G99 | Brain diseases | G00-G99 | CHRM5; |
| C00-D49: Neoplasms | Breast cancer | C50 | AR; CYP19A1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| NA: NA | Edema | NA | CA2; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Eczema | L20-L30 | NR3C1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Seborrhea | L21 | CHRM3; |
| C00-D49: Neoplasms | Bladder cancer | C67 | AR; CYP19A1; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | MMP2; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2; |
| NA: NA | Non-infectious rhinitis | NA | NR3C1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic macular edema | E08-E13, E08.3, E09.3, E10.3, E11.3, E13.3, H35.8, R60.9 | SERPINA6; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CHRM1; CHRM3; |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR; |
| C00-D49: Neoplasms | Advanced endometrium carcinoma | NA | PGR; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | CHRM1; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; CHRM1; CHRM5; |
| G00-G99: Diseases of the nervous system G00-G99 | Duchenne muscular dystrophy | G71.0 | NR3C1; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; |
| G00-G99: Diseases of the nervous system G00-G99 | Ataxia telangiectasia | G11.3 | NR3C1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | MMP1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Nausea | R11 | CHRM2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR; |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; CHRM2; NR3C2; |
| I00-I99: Diseases of the circulatory system | Heart arrhythmia | I47-I49 | CACNA1C; |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | CHRM5; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | FFAR1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | NR3C1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | CHRM1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | NR3C1; |
| N00-N99: Diseases of the genitourinary system | Gynecological disorder | N70-N98 | PGR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | NR3C1; SERPINA6; |
| NA: NA | Extrapyramidal disorders secondary to neuroleptic drug therapy | NA | CHRM1; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | AR; CHRM3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR; |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| Z00-Z99: Factors influencing health status and contact with health services | Hormonal contraceptives | Z30 | PGR; |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
| A00-B99: Certain infectious and parasitic diseases | Irritable bowel syndrome | A09, K58, K59.1 | CHRM1; CHRM5; |
| C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | CHRM1; CHRM3; |
| H60-H95: Diseases of the ear and mastoid process | Otitis externa | H60 | NR3C1; |
| N00-N99: Diseases of the genitourinary system | Overactive bladder | N32.81 | CHRM3; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR; PGR; |
| NA: NA | Abdominal stomach pain | NA | CHRM1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; MMP2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cushing's disease | E24.0 | NR3C1; |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | NR3C2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; |
| J00-J99: Diseases of the respiratory system | Obstructive lung diseases | J40-J44, J47 | CHRM3; |
| H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | NR3C1; |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR; |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Stabilize muscle contractions | M00-M99 | CHRM2; |
| K00-K95: Diseases of the digestive system | Stomach ulcer | K25-K27 | CHRM1; CHRM5; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cerebral salt-wasting syndrome | E87.1 | NR3C2; |
| N00-N99: Diseases of the genitourinary system | Menstrual disorders | N91-N95 | PGR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | CHRM1; CHRM5; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Postoperative nausea and vomiting | R11 | CHRM3; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
